المؤلفون: I. Gaydukova Z., O. Inamova V., R. Samigullina R., A. Chudinov L., A. Bychkova S., И. Гайдукова З., О. Инамова В., Р. Самигуллина Р., А. Чудинов Л., А. Бычкова С.

المساهمون: Исследование проведено в рамках НИР «Изучение общих и частных механизмов формирования и прогрессирования ревматических и сердечно-сосудистых заболеваний, а также разработка методов коррекции патогенетически значимых иммунных нарушений у данной категории больных» (РК ЕГИСУ АААА-А19-119053190037-1, 01.01.2019).

المصدر: Rheumatology Science and Practice; Vol 60, No 1 (2022); 32–37 ; Научно-практическая ревматология; Vol 60, No 1 (2022); 32–37 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: axial spondyloarthritis, non-radiographic axSpA, ankylosing spondylitis, etanercept, TNFα inhibitors, treatment efficacy, аксиальные спондилоартриты, нерентгенологический аксСпА, анкилозирующий спондилит, этанерцепт, ингибиторы ФНО-α, эффективность лечения

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3113/2153; Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013. doi:10.1038/nrdp.2015.13; Ritchlin C, Adamopoulos IE. Axial spondyloarthritis: New advances in diagnosis and management. BMJ. 2021;372:4447. doi:10.1136/bmj.m4447; Robinson PC, van der Linden S, Khan MA, Taylor WJ. Axial spondyloarthritis: Concept, construct, classification and implications for therapy. Nat Rev Rheumatol. 2021;17(2):109-118. doi:10.1038/s41584-020-00552-4; Гaйдукова ИЗ, Мазуров ВИ, Инамова ОВ, Трофимов ЕА, Василенко ЕА, Дубиков АИ, и др. Спондилоартриты: изменения в терминологии, классификации и диагностических подходах – от В.М. Бехтерева до наших дней. Терапия. 2019;8(34):118-130. doi:10.18565/therapy.2019.8.118-130; Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: Results of the ESTHER trial at week 48. Ann Rheum Dis. 2011;70(7):1257-1263. doi:10.1136/ard.2010.147033; Weiß A, Song IH, Haibel H, Listing J, Sieper J. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. Arthritis Res Ther. 2014;16(1):R35. doi:10.1186/ar4464; Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis – 3-year data of the ESTHER trial. Semin Arthritis Rheum. 2016;45(4):404-410. doi:10.1016/j.semarthrit.2015.08.005; Song IH, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, Listing J, et al. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: Data of the ESTHER trial. Rheumatology (Oxford). 2015;54(2):257-261. doi:10.1093/rheumatology/keu263; Rios Rodriguez V, Hermann KG, Weiß A, Listing J, Haibel H, Althoff C, et al. Progression of structural damage in the sacroiliac joints in patients with early axial spondyloarthritis during longterm anti-tumor necrosis factor treatment: Six-year results of continuous treatment with etanercept. Arthritis Rheumatol. 2019;71(5):722-728. doi:10.1002/art.40786; Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, et al. Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. Ann Rheum Dis. 2018;77(2):221-227. doi:10.1136/annrheumdis-2017-212008; Maksymowych WP, Claudepierre P, de Hooge M, Lambert RG, Landewé R, Molto A, et al. Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: A 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. Arthritis Res Ther. 2021;23(1):43. doi:10.1186/s13075-021-02428-8; Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, et al. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. Ann Rheum Dis. 2016;75(7):1328-1335. doi:10.1136/annrheumdis-2015-207596; Song IH, Weiß A, Hermann KG, Haibel H, Althoff CE, Poddubnyy D, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: Results from the ESTHER trial. Ann Rheum Dis. 2013;72(6):823-825. doi:10.1136/annrheumdis-2012-202389; Hendrix S, Koenig A, Li W, Singh A. Disease-modifying effect of etanercept versus sulphasalazine on spinal mobility in patients with ankylosing spondylitis. J Int Med Res. 2013;41(5):1606-1611. doi:10.1177/0300060513496171; Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15(3):R67. doi:10.1186/ar4244; Shim J, Jones GT, Pathan EMI, Macfarlane GJ. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and metaanalysis. Ann Rheum Dis. 2018;77(11):1578-1584. doi:10.1136/annrheumdis-2018-213590; Arends S, Brouwer E, Efde M, van der Veer E, Bootsma H, Wink F, et al. Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol. 2017;35(1):61-68.; van den Bosch F, Wei JCC, Nash P, Blanco FJ, Graham D, Zang C, et al. Etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: Results of RE-EMBARK, an open-label, phase IV trial. Ann Rheum Dis. 2020;79(Suppl 1);70. doi:10.1136/annrheumdis-2020-eular.1322; van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, et al. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford). 2012;51(10):1894-905. doi:10.1093/rheumatology/kes142; Lee SH, Lee SG, Kim YG, Kim YJ, Jeon JY, Yoo HJ, et al. Patients’ satisfactions to tumour necrosis factor inhibitors for management of ankylosing spondylitis in Korea; results from a multicentered, observational, and cross-sectional study. Ann Rheum Dis. 2020;79(Suppl 1);554. doi:10.1136/annrheumdis2020-eular.5090; Schmalzing M, Askari A, Sheeran T, Walsh D, De Toro Santos J, Vazquez Perez-Coleman JC, et al. Switching of treatment from reference etanercept to Sandoz etanercept biosimilar in patients with rheumatic diseases: An interim analysis of real-world data from the compact study. Ann Rheum Dis. 2021;80:540. doi:10.1136/annrheumdis-2021-eular.1490; https://rsp.mediar-press.net/rsp/article/view/3113

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3113
https://doi.org/10.47360/1995-4484-2022-32-37

المؤلفون: V. Mazurov I., E. Zotkin G., I. Gaydukova Z., E. Ilivanova P., T. Kropotina V., T. Plaksina V., O. Nesmeyanova B., N. Soroka F., E. Kunder A., E. Dokukina A., Yu. Linkova N., N. Kravtsova A., P. Pukhtinskaya S., A. Eremeeva V., A. Zinkina-Orikhan V., A. Lutckii A., В. Мазуров И., Е. Зоткин Г., И. Гайдукова З., Е. Иливанова П., Т. Кропотина В., Т. Плаксина В., О. Несмеянова Б., Н. Сорока Ф., Е. Кундер А., Е. Докукина А., Ю. Линькова Н., Н. Кравцова А., П. Пухтинская С., А. Еремеева В., А. Зинкина-Орихан В., А. Луцкий А.

المساهمون: Исследование выполнено при спонсорской поддержке ЗАО «БИОКАД». Спонсор участвовал в разработке проекта исследования и поддержке исследовательской программы, а также в принятии решения о представлении статьи для публикации. Конфликт интересов не повлиял на результаты исследования.

المصدر: Rheumatology Science and Practice; Vol 59, No 2 (2021); 141-151 ; Научно-практическая ревматология; Vol 59, No 2 (2021); 141-151 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: levilimab, monoclonal anti-IL-6 receptor antibody, rheumatoid arthritis, левилимаб, моноклональное антитело к рецептору ИЛ6, ревматоидный артрит

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3016/2074; Насонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.;2016:17-57. [Nasonov EL (ed.). Rheumatology: Russian clinical guidelines. Moscow;2019:17-57 (In Russ.)].; Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1; Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(17)32154-2; Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655; Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8(3):R66. doi:10.1186/ar1933; Paulshus Sundlisaeter N, Olsen IC, Aga AB, Hammer HB, Uhlig T, van der Heijde D, et al. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology (Oxford). 2018;57(11):2022-2031. doi:10.1093/rheumatology/key202; Khlyabova P, Eremeeva A, Lutckii A, Dokukina E, Chernyaeva E, Ivanov R. SAT0040: Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-IL6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers. Ann Rheum Dis. 2018;77(Suppl 2):884-885. doi:10.1136/annrheumdis-2018-eular.2410; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735. doi:10.1002/art.1780380602; Heegaard C, Dreyer L, Egsmose C, Madsen OR. Test-retest reliability of the disease activity score 28 CRP (DAS28-CRP), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints. Clin Rheumatol. 2013;32(10):1493-1500. doi:10.1007/s10067-013-2300-9; Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51(Suppl 6):vi16-vi20. doi:10.1093/rheumatology/kes281; van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261-263.; Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424-1437. doi:10.1002/art.39093; Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653-1661. doi:10.1002/acr.22384; 15. Mazurov V, Zotkin E, Ilivanova E, Kropotina T, Plaksina T, Nesmeyanova O, et al. FRI0108 Shot-term efficacy of BCD-089, novel monoclonal anti-IL6 receptor antibody, in combination with methotrexate in patients with rheumatoid arthritis: 12-week results of phase 2 AURORA Study. Ann Rheum Dis. 2019;78(Suppl 2):721.; Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277-290. doi:10.1002/art.39944; Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL6R alpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626-1634. doi:10.1136/ann-rheumdis-2013-204405; Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin 6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829. doi:10.1002/art.22033; Castagne B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019;14(8):e0220178. doi:10.1371/journal.pone.0220178; Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31-40. doi:10.1002/art.41095; https://rsp.mediar-press.net/rsp/article/view/3016

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3016
https://doi.org/10.47360/1995-4484-2021-141-151

المؤلفون: T. Korotaeva V., V. Mazurov I., A. Lila M., I. Gaydukova Z., A. Bakulev L., A. Samtsov V., V. Khairutdinov R., A. Zinkina-Orikhan V., Yu. Sevastyanova A., A. Eremeeva V., Т. Коротаева В., В. Мазуров И., А. Лила М., И. Гайдукова З., А. Бакулев Л., А. Самцов В., В. Хайрутдинов Р., А. Зинкина-Орихан В., Ю. Севастьянова А., А. Еремеева В.

المصدر: Rheumatology Science and Practice; Vol 59, No 1 (2021); 47-55 ; Научно-практическая ревматология; Vol 59, No 1 (2021); 47-55 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: netakimab, psoriatic arthritis, interleukin-17 inhibitors, нетакимаб, псориатический артрит, ингибиторы интерлейкина-17

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2989/2058; Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665. doi:10.12688/f1000research.19144.1; Van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22(1):18. doi:10.1186/s13075-020-2103-8; Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–2096. doi:10.1056/NEJMc1704342; Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2). doi:10.3390/ijms19020530; Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379−390. doi:10.1007/s12016-018-8702-3; Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950−957. doi:10.1038/ni1497; Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272−1281. doi:10.1002/art.38376; Мазуров ВИ, Эрдес ШФ, Гайдукова ИЗ, Дубинина ТВ, Пристром АМ, Кундер ЕВ и др. Долгосрочная эффективность и безопасность нетакимаба при лечении анкилозирующего спондилита: результаты международного многоцентрового рандомизированного двойного слепого клинического исследования III фазы BCD-085-5/ASTERA. Современная ревматология. 2020;14(4):39−49. doi:10.14412/1996-7012-2020-4-39-49; Кубанов АА, Бакулев АЛ, Самцов АВ, Хайрутдинов ВР, Соколовский ЕВ, Кохан ММ и др. Нетакимаб – новый ингибитор ИЛ-17А: результаты 12 недель клинического исследования III фазы BCD-085-7/PLANETA у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Вестник дерматологии и венерологии. 2019;95(2):15−28. doi:10.25208/0042-4609-2019-95-2-15-28; Коротаева ТВ, Мазуров ВИ, Лила АМ, Гайдукова ИЗ, Бакулев АЛ, Самцов АВ и др. Эффективность и безопасность нетакимаба у пациентов с псориатическим артритом: результаты клинического исследования III фазы PATERA. Научно-практическая ревматология. 2020;58(5):480–488. doi:10.47360/1995-4484-2020-480-488; Коротаева ТВ, Самцов АВ, Хайрутдинов ВР, Бакулев АЛ, Младов ВВ, Еремеева АВ и др. Эффективность нетакимаба у пациентов с псориатическим артритом, ранее не получавших ингибиторы фактора некроза опухоли a: субанализ результатов исследования PATERA. Consilium Medicum. 2020;22(7):14−19. doi:10.26442/20751753.2020-7.200319; Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665−2673. doi:10.1002/art.21972; Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5-21. doi:10.1177/2040622317738910; Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR., et al. Safety of ixekizumab in patients with psoriatic arthritis: Results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367−378. doi:10.1002/acr.23738; Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317−2327. doi:10.1016/S0140-6736(17)31429-0; Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2):e000723. doi:10.1136/rmdopen-2018-000723; McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137−1146. doi:10.1016/S0140-6736(15)61134-5; Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79−87. doi:10.1136/annrheumdis-2016-209709; Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Shortand long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432−440. e17. doi:10.1016/j.jaad.2016.09.026; https://rsp.mediar-press.net/rsp/article/view/2989

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2989
https://doi.org/10.47360/1995-4484-2021-47-55

المؤلفون: V. Mazurov I., I. Gaydukova Z., Sh. Erdes, T. Dubinina V., A. Pristrom M., E. Kunder V., N. Soroka F., A. Kastanayan A., T. Povarova V., E. Zhugrova S., T. Plaksina V., P. Shesternya A., T. Kropotina V., O. Antipova V., E. Smolyarchuk A., O. Tciupa A., D. Abdulganieva I., S. Lapshina A., D. Krechikova G., I. Gordeev G., O. Nesmeyanova B., V. Tyrenko V., E. Ilivanova P., A. Strelkova V., A. Eremeeva V., В. Мазуров И., И. Гайдукова З., Ш. Эрдес, Т. Дубинина В., А. Пристром М., Е. Кундер В., Н. Сорока Ф., А. Кастанаян А., Т. Поварова В., Е. Жугрова С., Т. Плаксина В., П. Шестерня А., Т. Кропотина В., О. Антипова В., Е. Смолярчук А., О. Цюпа А., Д. Абдулганиева И., С. Лапшина А., Д. Кречикова Г., И. Гордеев Г., О. Несмеянова Б., В. Тыренко В., Е. Иливанова П., А. Стрелкова В., А. Еремеева В.

المساهمون: Funding: this study was supported by JSC BIOCAD., Исследование спонсировалось ЗАО «БИОКАД».

المصدر: Rheumatology Science and Practice; Vol 58, No 4 (2020); 376-386 ; Научно-практическая ревматология; Vol 58, No 4 (2020); 376-386 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: netakimab, BCD-085, monoclonal antibody, interleukin 17A, ankylosing spondylitis, axial spondyloarthritis, нетакимаб, интерлейкин 17А, моноклональное антитело, анкилозирующий спондилит, аксиальный спондилоартрит

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2925/2002; Лапшина СА, Дубинина ТВ, Бадокин ВВ и др. Ингибиторы фактора некроза опухоли А в лечении аксиальных спондилоартритов, включая анкилозирующий спондилит. Научнопрактическая ревматология. 2016;54(1S):75-79 doi:10.14412/1995-4484-2016-1S-75-79; Белов БС. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научно-практическая ревматология. 2014;52(3):322-330. doi:10.14412/1995-4484-2014-322-330; Prado MS, Bendtzen K, Andrade LEC. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events. Expert Opin Drug Metab Toxicol. 2017;13(9): 985-95. doi:10.1080/17425255.2017.1360280.; Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13(12):707-18. doi:10.1038/nrrheum.2017.187; Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open. 2017;3(1):e000284. doi:10.1136/rmdopen-2016-000284; Cheung PP. Anti-IL17A in Axial Spondyloarthritis-Where Are We At? Front Med (Lausanne). 2017;4:1. doi:10.3389/fmed.2017.00001; Tahir H. Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology (Oxford). 2018; 57(suppl6):vi23– vi28. doi:10.1093/rheumatology/key152; Van der Heijde D, Cheng-Chu Wei J, Dougados M, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16-week results of a phase 3 randomised, double-blind, active-controlled and placebocontrolled trial. Lancet. 2018;392(10163):2441-51. doi:10.1016/ S0140-6736(18)31946-9; Baeten D, Sieper J, Braun J, et al. Secukinumab, an Interleukin17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373(26):2534–48. doi:10.1056/NEJMoa1505066; Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol Hoboken NJ. 2019;71(4):599–611. doi:10.1002/art.40753; Van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–91. doi:10.1136/annrheumdis-2016-210770; Насонов ЕЛ. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.; Torgutalp M, Poddubnyy D. IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin Biol Ther. 2019;6:1-11. doi:10.1080/14712598.2019.1605352; Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1): 50-55; Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2017;176(3):752-58. doi:10.1111/bjd.14965; Mazurov V, Erdes S, Kunder E, et al. OP0028 Efficacy and safety of BCD-085, a novel il-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study. Ann Rheum Dis. 2018;77(2). doi:10.1136/annrheumdis-2018-eular.2380; Samtsov AV, Khairutdinov VR, Bakulev AA, et al. Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis. Vestnik Dermatologii i Venerologii. 2017;5:52– 63. doi:10.25208/0042-4609-2017-93-5-52-63; Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68 (suppl 2): ii1–44. doi:10.1136/ard.2008.104018; Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument, Pharmacoeconomics, 1993; 4 (pg. 353-65). doi:10.2165/00019053-199304050-00006; Lins L, Carvalho FM. SF-36 total score as a single measure of health-related quality of life: Scoping review. SAGE Open Med. 2016;4:2050312116671725. doi:10.1177/2050312116671725; Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48(4):1126–36. doi:10.1002/art.10883; Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(5):703-9. doi:10.1002/art.21445; ICH E2A Clinical safety data management: definitions and standards for expedited reporting. 1995; Гайдукова ИЗ, Ребров АП, Лапшина СА и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-484. doi:10.14412/1995-4484-2017-474-484; Cosentyx Assessment report. EMA/CHMP/389874/2014 26. Taltz Assessment report. EMA/59447/2018; https://rsp.mediar-press.net/rsp/article/view/2925

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2925
https://doi.org/10.47360/1995-4484-2020-376-386

المؤلفون: Sh. Erdes, V. Mazurov I., T. Dubinina V., I. Gaydukova Z., S. Lapshina A., E. Zonova V., D. Krechikova G., T. Plaksina V., O. Reshetko V., S. Smakotina A., P. Shesternya А., I. Gordeev G., T. Makulova G., T. Povarova V., T. Raskina A., N. Soroka F., A. Pristrom M., E. Kunder V., Yu. Usacheva V., E. Stukalina Yu., A. Eremeeva V., E. Chernyaeva V., R. Ivanov A., Ш. Эрдес, В. Мазуров И., Т. Дубинина В., И. Гайдукова З., С. Лапшина А., Е. Зонова В., Д. Кречикова Г., Т. Плаксина В., О. Решетько В., С. Смакотина А., П. Шестерня А., И. Гордеев Г., Т. Макулова Г., Т. Поварова В., Т. Раскина А., Н. Сорока Ф., А. Пристром М., Е. Кундер В., Ю. Усачева В., Е. Стукалина Ю., А. Еремеева В., Е. Черняева В., Р. Иванов А.

المساهمون: Спонсор исследования — ЗАО «БИОКАД». Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать

المصدر: Rheumatology Science and Practice; Vol 57, No 6 (2019); 668-677 ; Научно-практическая ревматология; Vol 57, No 6 (2019); 668-677 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: ankylosing spondylitis, radiographic axial spondyloarthritis, BCD-085, interleukin 17A inhibitor, анкилозирующий спондилит, рентгенологический аксиальный спондилоартрит, ингибитор интерлейкина 17А

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2804/1905; Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60. doi:10.14412/1995-4484-2015-657-660; Эрдес ШФ, Ребров АП, Дубинина ТВ и др. Спондилоартриты: современная терминология и определения. Терапевтический архив. 2019;91(5):84-8 doi:10.26442/00403660.2019.05.000208; Sieper J, Braun J, Dougados M, Baeten D. Axial spondyloarthri-tis. Nat Rev Dis Prim. 2015 Jul 9;1:15013. doi:10.1038/nrdp.2015.13; Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-90. doi:10.1016/S0140-6736(07)60635-7; Landewe R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68(6):863-7. doi:10.1136/ard.2008.091793; Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol. 2011;7:700-7. doi:10.1038/nrrheum.2011.156; Liu W, Wu YH, Zhang L, et al. Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis. Int J Clin Exp Med. 2015;8(10):17362-76.; De Koning A, Schoones JW, van der Heijde D, van Gaalen FA. Pathophysiology of axial spondyloarthritis: consensus and controversies. Eur J Clin Invest. 2018;48(5):e12913. doi:10.1111/eci.12913; Zambrano-Zaragoza JF, Agraz-Cibrian JM, Gonzalez-Reyes C, et al. Ankylosing spondylitis: from cells to genes. Int J Inflam. 2013;2013:501653. doi:10.1155/2013/501653; Osta B, Lavocat F, Eljaafari A, Miossec P. Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol. 2014;5:425. doi:10.3389/fimmu.2014.00425; Gravallese EM, Schett G. Effects of the IL-23—IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;14:631-40. doi:10.1038/s41584-018-0091-8; Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):731-41. doi:10.1038/nrrheum.2017.188; Гайдукова ИЗ, Ребров АП, Лапшина СА и др. Применение нестероидных противовоспалительных препаратов и генноинженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-84. doi:10.14412/1995-4484-2017-474-484; Lee J-W, Kang J-H, Yim Y-R, et al. Predictors of switching antitumor necrosis factor therapy in patients with ankylosing spondylitis. Rosenbaum JT, ed. PLoSOne. 2015;10(7):e0131864. doi:10.1371/journal.pone.0131864; Baraliakos X, Braun J, Deodhar A, et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Ann Rheum Dis. 2018;77:997-98. doi:10.1136/annrheumdis-2018-eular.1396; Насонов ЕЛ, Мазуров ВИ, Усачева ЮВ и др. Разработки отечественных оригинальных генно-инженерных биологических препаратов для лечения иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2017;55(2):201-10. doi:10.14412/1995-4484-2017-201-210; Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534-48. doi:10.1056/NEJMoa1505066; Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011 Sep;134(1):8-16. doi:10.1111/j.1365-2567.2011.03465.x; Baraliakos X, Braun J, Deodhar AA, et al. Long-term evaluation of secukinumab in ankylosing spondylitis: 5 year efficacy and safety results from a phase 3 trial [abstract]. Arthritis Rheum. 2018;70 Suppl 10. Available from: https://acrabstracts.org/abstract/long-term-evaluation-of-secukinumab-in-ankylosing-spondylitis-5-year-efficacy-and-safety-results-from-a-phase-3-trial/. Accessed November 8, 2018.; Martinis F, Caimmi C, Carletto A, et al. AB0833 Real-world efficacy and safety of secukinumab: data from verona’s cohort. Ann Rheum Dis. 2018;77:1534-48. doi:10.1136/annrheumdis-2018-eular.1799; Arbabi-Ghahroudi M. Camelid single-domain antibodies: Historical perspective and future outlook. Front Immunol. 2017;8:1589. doi:10.3389/fimmu.2017.01589; https://rsp.mediar-press.net/rsp/article/view/2804

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2804
https://doi.org/10.14412/1995-4484-2019-668-677

المؤلفون: A. Akulova I., A. Rebrov P., Sh. Erdes, I. Gaydukova Z., А. Акулова И., А. Ребров П., Ш. Эрдес, И. Гайдукова З.

المصدر: Rheumatology Science and Practice; Vol 57, No 3 (2019); 294-298 ; Научно-практическая ревматология; Vol 57, No 3 (2019); 294-298 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: ASAS Health Index, spondyloarthritis, ankylosing spondylitis, quality of life, patient health, индекс здоровья ASAS, спондилоартриты, анкилозирующий спондилит, качество жизни, здоровье пациентов

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2729/1845; Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3-17. doi:10.1136/annrheumdis-2017-211734; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi:10.1136/annrheumdis-2016-210770; Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.; Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patient with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18-24. doi:10.1136/ard.2008.094870; Dougados M, Braun J, Burgos-Vargas R, et al. ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis [letter]. Ann Rheum Dis. 2012;71:1103-4. doi:10.1136/annrheumdis-2011-201038; Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281-5.; Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994; 21(9):1694-8.; Kwan YH, Fong WW, Lui NL, et al. Validity and reliability of the Short Form 36 Health Surveys (SF-36) among patients with spondyloarthritis in Singapore. Rheumatol Int. 2016;36(12):1759-65. doi:10.1007/s00296-016-3567-3; Акулова АИ, Гайдукова ИЗ, Ребров АП. Валидация версии 5L опросника EQ-5D в России. Научно-практическая ревматология. 2018;56(3):351-5 [Akulova AI, Gaydukova IZ, Rebrov AP. Validation of the EQ-5D-5L version in Russia. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):351-5 (In Russ.)]. doi:10.14412/1995-4484-2018-351-355; Гайдукова ИЗ, Акулова АИ, Ребров АП и др. Перевод и адаптация русскоязычной версии индекса здоровья ASAS (ASAS HEALTH INDEX). Научно-практическая ревматология. 2019;57(1):56-61 [Gaidukova IZ, Akulova AI, Rebrov AP, et al. Adaptation of the Russian version of the ASAS health index. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):56-61 (In Russ.)]. doi:10.14412/1995-4484-2019-56-61; Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74(5):830-5. doi:10.1136/annrheumdis-2013-203967; Kiltz U, van der Heijde D, Cieza A, et al. Developing and validating an index for measuring health in patients with ankylosing spondylitis. Rheumatology. 2011;50:894-8. doi:10.1093/rheumatology/keq315; Kiltz U, van der Heijde D, Boonen A, Braun J. The ASAS Health Index (ASAS HI) – a new tool to assess the health status of patients with spondyloarthritis. Clin Exp Rheumatol. 2014;32(5 Suppl 85):105-8.; Kiltz U, van der Heijde D, Boonen A, et al. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. RMD Open. 2016;2:e000311. doi:10.1136/rmdopen-2016-000311; Kiltz U, van der Heijde D, Boonen A, et al. Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis. 2018;77(9):1311-7. doi:10.1136/annrheumdis-2017-212076; Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (Part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi:10.1136/ard.2009.108233; Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31. doi:10.1136/ard.2010.133645; Maksymowych WP, Richardson R, Mallon C, et al. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum. 2007;57(1):133-9. doi:10.1002/art.22469; Амирджанова ВН, Койлубаева ГМ. Методология оценки качества жизни в практике ревматолога. Научно-практическая ревматология. 2003;41(2):72-6 [Amirdzhanova VN, Kojlubaeva GM. Methodology for assessing the quality of life in the practice of rheumatologist. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(2):72-6 (In Russ.)]. doi:10.14412/1995-4484-2003-773; Choi JH, Kim TJ, Shin K, et al. The reliability and validity of a Korean translation of the ASAS Health Index and Environmental Factors in Korean patients with axial spondyloarthritis. Korean Med Sci. 2014;29(3):334-7. doi:10.3346/jkms.2014.29.3.334; Bautista-Molano W, Landewe RBM, Kiltz U, et al. Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. Clin Rheumatol. 2018;37(11):3063-8. doi:10.1007/s10067-018-4308-7; Di Carlo M, Lato V, Carotti M, Salaffi F. Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis. Health Qual Life Outcom. 2016;14:78. doi:10.1186/s12955-016-0463-1; Поддубный ДА, Ребров АП. Оценка качества жизни больных анкилозирующим спондилитом. Научно-практическая ревматология. 2006;44(2):105 [Poddubnyy D, Rebrov AP. Assessment of the quality of life of patients with ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2006;44(2):105 (In Russ.)].; https://rsp.mediar-press.net/rsp/article/view/2729

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2729
https://doi.org/10.14412/1995-4484-2019-294-298

المؤلفون: A. Akulova I, I. Gaydukova Z., A. Rebrov P., А. Акулова И., И. Гайдукова З., А. Ребров П.

المصدر: Rheumatology Science and Practice; Vol 56, No 3 (2018); 351-355 ; Научно-практическая ревматология; Vol 56, No 3 (2018); 351-355 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20183

مصطلحات موضوعية: spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, quality of life, EQ-5D-5L, спондилоартриты, анкилозирующий спондилит, псориатический артрит, качество жизни

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2571/1718; Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379-90. doi:10.1016/S0140-6736(07)60635-7; Эрдес ШФ. Развитие концепции спондилоартритов. Научнопрактическая ревматология. 2014;52(5):474-6 [Erdes ShF. The development of the concept of spondyloarthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):474-6 (In Russ.)]. doi:10.14412/1995-4484- 2014-574-576; Эрдес ШФ. Стратегия «лечение до достижения цели» при спондилоартритах. Научно-практическая ревматология. 2014;52(3):251-3 [Erdes ShF. «Treating to target» strategy in spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):251-3 (In Russ.)]. doi:10.14412/1995-4484-2014-251-253; Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904. doi:10.1136/ard.2011.151027; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi:10.1136/annrheumdis-2016-210770; Новик АА, Ионова ТИ. Руководство по исследованию качества жизни в медицине. Санкт-Петербург: Олма-Пресс; 2002. 300с. [Novik AA, Ionova TI. Rukovodstvo po issledovaniju kachestva zhizni v medicine [Guide to the study of quality of life in medicine]. St-Petersburg: Olma-Press; 2002. 300 p. (In Russ.)].; Амирджанова ВН, Койлубаева ГМ. Методология оценки качества жизни в практике ревматолога. Научно-практическая ревматология. 2003;41(2):72-6 [Amirdzhanova VN, Kojlubaeva GM. The methodology of evaluation of quality of life in the practice of the rheumatologist. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(2):72-6 (In Russ.)]. doi:10.14412/1995-4484-2003-773; Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisa. Ann Rheum Dis. 2009;68(6):770-6. doi:10.1136/ard.2009.108217; Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (Part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi:10.1136/ard.2009.108233; Rudwaleit M, Landewe R, van der Heijde D, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25-31. doi:10.1136/ard.2010.133645; Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Rheumatology. 1994;21(12):2286-91.; Machado P, LandewE R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activitystates and improvement scores. Ann Rheum Dis. 2011;70(1):47-53. doi:10.1136/ard.2010.138594; Calin A, Garret S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21(12):2281-5.; Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21(9):1694-8.; Kiltz U, van der Heijde D, Boonen A, et al. Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis. 2015;74(5):830-5. doi:10.1136/annrheumdis2013-203967; Kwan YH, Fong WW, Lui NL, et al. Validity and reliability of the Short Form 36 Health Surveys (SF-36) among patients with spondyloarthritis in Singapore. Rheumatol Int. 2016;36(12):1759- 65. doi:10.1007/s00296-016-3567-3 17. Bruce B, Fries JF. The HAQ. Clin Exp Rheum. 2005;23(39):14-8.; https://rsp.mediar-press.net/rsp/article/view/2571

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2571
https://doi.org/10.14412/1995-4484-2018-351-355